[1] Roersma F, Harrington RA, Moliterno DJ. Platelet glycoprotein Ⅱb / IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J].Lancet, 2002,359:189-198. [2] 中华医学会心血管病学分会.急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志,2010,38(8):675-690. [3] Razakjr OA, Tan HC, Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention[J]. J Interv Cardiol, 2005,18(1):33-37. [4] 陈灏珠,何梅先,葛均波,等.实用心脏病学[M].4版.上海:上海科学技术出版社,2007:888-890. [5] Suades R, Padró T, Vilahur G. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques[J]. Thromb Haemost,2012,108(6):1208-1219. [6] 解畅.GPIIb/IIIa受体拮抗剂对血小板释放PMPs及VEGF、TXA2的影响[D].天津:天津医科大学,2012. [7] Steinhubl SR, Talley JD, Braden GA, et al.Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention:results of the GOLD (AUoAssessing Uhegra) multicenter study[J].Circulation,2001, 103(21): 2572-2578. [8] Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement[J]. Clin Ther, 2002,24(8):1332-1344. [9] Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes[J]. N Engl J Med, 2009, 360(21):2176-2190. [10] Choussat R, Black A, Bossi I, et al.Vascular complications and clinical outcome after coronary angioplasty with platelet Iib/IIIa receptor blockade[J]. Eur Heart J, 2000, 21(8): 662-667. |